2-CAR T Cell Therapy for Diffuse Intrinsic Pontine Glioma and Spinal Cord Diffuse Midline Glioma | Neurology Grand Rounds (RECORDING)

Tuesday, November 26, 2024, 12:00 AM - Thursday, November 25, 2027, 11:59 PM, On Demand

In this recorded Neurology Grand Rounds presentation, Director of the Neuro-Immuno-Oncology Program and Professor of Pediatric Neuro-Oncology at Stanford Medicine Dr. Michelle Monje and Dr. Jasia Mahdi (Co-Primary Investigator) discuss their clinical trial for GD2 CAR T-cell therapy in diffuse midline gliomas (DMGs). Dr. Monje introduces the topic of diffuse midline gliomas (DMGs), particularly focusing on diffuse intrinsic pontine gliomas (DIPGs). She describes these as fatal malignancies with a median survival of only 10-11 months for DIPG. Dr. Monje explains that these tumors integrate structurally and electrically with neural circuits, making them challenging to treat. Dr. Monje then explains that her laboratory identified GD2 as a promising target on the surface of DIPG cells. This disialoganglioside is highly expressed on tumors with the H3K27M mutation, which is present in over 80% of DMGs. The discovery led to collaboration with Dr. Crystal Mackall to develop optimized GD2-targeting CAR T-cells. Dr. Mahdi then concludes the lecture with exciting updates on the clinical trial

  Release Date: November 26, 2024
  Expiration Date: November 25, 2027
  Estimated Time to Complete: 0.5 hours
  Registration Fee: FREE
 *Originally recorded 01/05/2024

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours)

1. Explore different administration routes and dosing regimens for GD2 CAR T therapy to improve efficacy and tolerability.
2. Discuss the importance of studying the tumor microenvironment and factors contributing to tumor growth and resistance to develop more durable responses.
3. Highlight the need for a multidisciplinary approach in delivering GD2 CAR T therapy safely, involving collaboration with neurology colleagues.
4. Identify the long-term outcomes of patients who showed significant responses, such as the patient with a complete response sustained for over 20 months.
5. Investigate the role of lymphodepleting chemotherapy in inducing more durable responses with ICV infusions.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Office.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography click HERE

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity. 

Faculty Member Information	Role in activity	Name of commercial interest/Nature of relationship
Kate Therkelsen, MD	Course Director	Nothing to Disclose
Tara Torabi, MD	Planner	Nothing to Disclose
Rachel Walsh, MD	Planner	Nothing to Disclose
Gregory Wong, MD	Planner and Reviewer	Nothing to Disclose
Jose Eduardo Espindola Lima, MD	Planner and Reviewer	Nothing to Disclose
Michelle Monje, MD, PhD	Faculty	Advisor - Cygnal Therapeutics (Relationship has ended)
Jasia Mahdi, MD	Faculty	Nothing to disclose